Intrathecal gene therapy in mouse models expressing CMT1X mutations
| Autor: | George Lapathitis, Kleopas A. Kleopa, Alexia Kagiava, Jan Richter, Christos Karaiskos, Irene Sargiannidou, Christina Christodoulou, Christina Tryfonos |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine Transgene Genetic enhancement Genetic Vectors Mutant Gene Expression Golgi Apparatus Biology Gene mutation Endoplasmic Reticulum medicine.disease_cause Connexins Mice 03 medical and health sciences Myelin 0302 clinical medicine Charcot-Marie-Tooth Disease Gene expression Genetics medicine Animals Humans Molecular Biology Gene Injections Spinal Genetics (clinical) Mice Knockout Mutation Lentivirus Gap Junctions Genetic Therapy General Medicine Molecular biology 3. Good health Disease Models Animal 030104 developmental biology medicine.anatomical_structure Schwann Cells 030217 neurology & neurosurgery |
| Zdroj: | Human Molecular Genetics |
| ISSN: | 1460-2083 0964-6906 |
| DOI: | 10.1093/hmg/ddy056 |
| Popis: | Gap junction beta-1 (GJB1) gene mutations affecting the gap junction protein connexin32 (Cx32) cause the X-linked Charcot-Marie-Tooth disease (CMT1X), a common inherited neuropathy. Targeted expression of virally delivered Cx32 in Schwann cells following intrathecal injection of lentiviral vectors in the Cx32 knockout (KO) mouse model of the disease has led to morphological and functional improvement. To examine whether this approach could be effective in CMT1X patients expressing different Cx32 mutants, we treated transgenic Cx32 KO mice expressing the T55I, R75W or N175D CMT1X mutations. All three mutants were localized in the perinuclear compartment of myelinating Schwann cells consistent with retention in the ER (T55I) or Golgi (R75W, N175D) and loss of physiological expression in the non-compact myelin. Following intrathecal delivery of the GJB1 gene we detected the virally delivered wild-type (WT) Cx32 in non-compact myelin of T55I KO mice, but only rarely in N175D KO or R75W KO mice, suggesting dominant-negative effects of the R75W and N175D mutants but not of the T55I mutant on co-expressed WT Cx32. GJB1 treated T55I KO mice showed improved motor performance, lower ratios of abnormally myelinated fibers and reduction of inflammatory cells in spinal roots and peripheral nerves compared with mock-treated littermates. Either partial (N175D KO) or no (R75W KO) improvement was observed in the other two mutant lines. Thus, certain CMT1X mutants may interfere with gene addition therapy for CMT1X. Whereas gene addition can be used for non-interfering CMT1X mutations, further studies will be needed to develop treatments for patients harboring interfering mutations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|